Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Better load up boosters rolling out next week. And more to come in coming weeks. $$$$. 100 plus 6 months.
$TXTM Looks like no debt in Filings Looks like RSA paid off All Debts in Deal I see us hitting long term ,10-.17 plus$$$
Do your dd in Buying any stock!
Load up another booster coming. And more coming with $PFE$
FREY
Question is how far can this go
Going to $100 longterm
$100 plus Longterm
Due time we will be at Multi Cents $$
$100 plus Longterm $$
100 plus nice and easy that’s where this Stock belongs $$
Good Morning. Get to .002 we will run.
$PLPL This one is a Beauty $$.
$PLPL this one is a Beauty $$ .0017 not for long $
Good Morning let’s get to .002 break will get to .005 fast $$$
PLPL .0011
PLPL this will see multi cents .0011 reverse merger done $$$
This one going to be Huge MMS playing games. Going to be wild $$$
Going over $100 plus soon. $$
Break that .02 cents we fly$$
Good Morning. Looks like a run in the making :)
$TXTM Get ready for a run over .10 cents $
$TXTM
June watch the move $$
$PFE working on Monkeypox antidote. $$
Wow what happened here.
Multi cents coming $$
Pfizer to Bolster RSV Vaccination Through Acquisition
April 08 2022 - 09:55AM
TipRanks
Print
Share On Facebook
Pfizer (PFE) has agreed to acquire British antiviral drug developer ReViral for $525 million. PFE stock rose more than 4.3% to close at $55.16 on April 7. The New York-headquartered Pfizer is a multinational pharmaceutical company. Its portfolio includes therapies and vaccines for various diseases, and it is one of the manufacturers of COVID-19 vaccines. Meanwhile, ReViral is developing treatments for respiratory syncytial virus (RSV) and has several drug candidates in the pipeline. Its flagship drug candidate, sisunatovir, is in a Phase 2 study. The experimental drug has been tested in adults with promising results, and now it is being tried in infants.
https://www.tipranks.com/news/pfizer-to-bolster-rsv-vaccination-through-acquisition?utm_source=advfn.com&utm_medium=referral
$100 plus coming $PFE scooping up companies a lot of cash on hand $$
Looking for a Huge run any day $$
Going to $100 plus.
$PFE going to $500 plus Longterm. A lot of cash on hand $$$
Watch $PFE go to $500 plus where it belongs long term$$!
NOUV going to Muti cents $$
Going to go up and up $$$
Never going to $$$$$$$$$$$$$
Electric is where it’s at This one will shoot to the stars $$$
$PFE. Going to $100 plus
I take back target of $60 going to $500 plus they are buying up companies big money cash on hand. Start loading up going longterm $500 plus.
Going to $60 plus $PFE has all of cash on hand going after other company’s. $$.